Humanigen is not currently accepting enquiries regarding lenzilumab™ for emergency use.

​

Humanigen has announced positive Phase 3 topline results in Patients with COVID-19. For more information, view our press release or visit ClinicalTrials.gov (Identifier: NCT04351152)

​

See also:

​

Mayo Clinic Study of Humanigen’s Lenzilumab Shows Rapid Recovery and Discharge in Severe and Critical COVID-19 Patients (more information)

​

Humanigen Reports Additional Analysis of Lenzilumab in Severe and Critical COVID-19 Patients (more information)